Loading clinical trials...
Loading clinical trials...
A Randomized Controlled, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Combination Therapy With Serplulimab and RT in Patients With ES-SCLC Who Have Not Progressed After Treat With Serplulimab Combined Chemotherapy
Conditions
Interventions
Serplulimab
Chest Radiation
Locations
1
China
Zhejiang Cancer Hospital
Hangzhou, China
Start Date
October 18, 2023
Primary Completion Date
December 31, 2024
Completion Date
December 31, 2025
Last Updated
April 5, 2024
Lead Sponsor
Zhejiang Cancer Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions